Two studies address alarm fatigue in ICU

Alarm fatigue within the intensive care unit (ICU) can negatively impact patient safety and lead to life-threatening events. Researchers from Harlem Hospital and Maimonides Medical Center aimed to identify solutions fight such fatigue.

The first study from New York's Harlem Hospital, published in Chest, set out to examine alarm frequency with a goal of decreasing response time to less than 60 seconds. Researchers audited all clinical alarm-sounding devices. In the 20-bed ICU, researchers were able to decrease alarm rates by 70 percent at four months after intervention.

“After an intensive educational process involving all clinicians and increasing the threshold at which alarms went off, the frequency of alarms and response time decreased significantly with the greatest reduction seen in the bedside monitor,” concluded first author Afua Kunadu and colleagues. "The reduction in alarm rate and improved response could be attributed to educational efforts, staff recognition that the alarms are now more actionable, or may be due to a reduction in alarm fatigue. These interventions, by themselves, were insufficient to decrease response time for all alarms to less than 60 seconds”

The second study, conducted at Brooklyn's Maimonides Medical Center and also published in Chest, analyzed accuracy of cardiac monitor alarms in the ICU. Over the course of a year, researchers collected data on 2,408 alarms occurring among 350 patients. Results found a large number were false alarms without any clinical significance.

“Alarm fatigue ranked first on the list of 'Top 10 Health Technology Hazards' released by Emergency Care Research Institute in 2012, 2013 and 2015. With this study, we highlight a pressing need of implementing an intelligent cardiac monitoring system in the ICUs. Besides being highly sensitive, the alarm system should also take into account other parameters before beeping,” concluded first author Parita Soni and colleagues. “Reducing the number of [false] alarms would lead to increased efficiency of the nursing staff and other medical personnel; hence would improve the patient safety.”

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.